⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065687 | 0.70 | — | — | |
| SCHEMBL256092 | 0.67 | — | — | |
| SCHEMBL1358702 | 0.67 | — | — | |
| SCHEMBL12778254 | 0.67 | — | — | |
| SCHEMBL22125849 | 0.67 | — | — | |
| SCHEMBL803748 | 0.67 | — | — | |
| SCHEMBL8508536 | 0.67 | — | — | |
| SCHEMBL1246645 | 0.67 | — | — | |
| SCHEMBL20239803 | 0.65 | ALDH1A1 (0.40) | — | |
| SCHEMBL709632 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746964-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2026046976-A1 | PYRAZOLOPYRIDINE PHOSPHATE ESTERS FOR MODULATING SALT-INDUCIBLE KINASE (SIK) | F. HOFFMANN-LA ROCHE AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-2029602-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2008130570-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |